Two years of treatment with oral icotrokinra (Icotyde, Johnson & Johnson) produced IGA 0/1 — clear or almost clear skin — in 70% of plaque psoriasis patients, up from 57% at Week 16, according to Phase 3 ICONIC-TOTAL data presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria.

The trajectory was continuous. IGA 0/1 rates rose from 57% at Week 16 to 67% at Week 24, then to 70% at Week 112. The findings cover patients across high-impact anatomical sites — scalp, genitals, hands, feet and nails — where residual disease drives disproportionate quality-of-life burden and where many clinicians still consider durable clearance an unmet need.

What did the site-specific clearance data show?

At Week 112, icotrokinra-treated patients achieved complete clearance at high-impact sites at the following rates:

• Scalp: 60% of patients with scalp psoriasis reached a scalp-specific Investigator's Global Assessment (ss-IGA) score of 0.
• Genitals: 89% of patients with genital psoriasis achieved a Physician's Global Assessment of Genitalia (sPGA-G) score of 0.
• Hands and/or feet: 63% of patients with palmoplantar involvement achieved a hand and/or foot Physician's Global Assessment (hf-PGA) score of 0.

Nail disease followed a slower but steady curve. Mean percentage improvement on the modified Nail Psoriasis Severity Index (mNAPSI) climbed from 33% at Week 16 to 62% at Week 52 and reached 71% at Week 112. That continued gain between Year 1 and Year 2 suggests nail clearance keeps accruing with sustained oral therapy, in contrast to the earlier plateau seen in cutaneous endpoints.

How did safety hold up over two years?

Safety findings through Week 112 remained consistent with icotrokinra's established profile, with no new safety signals identified, Johnson & Johnson reported. The company framed the durability-plus-safety combination as the central argument for the agent's place in the plaque psoriasis armamentarium.

“These robust two-year data validate that ICOTYDE provides enduring skin clearance with a favorable safety profile, making it a pivotal advancement in plaque psoriasis treatment,” said Richard B. Warren, MD, PhD, Professor of Dermatology at the University of Manchester, Manchester, UK, in a news release.

Warren's statement is a company-issued characterization; the underlying figures — the IGA 0/1, ss-IGA, sPGA-G, hf-PGA and mNAPSI results — come from the Phase 3 ICONIC-TOTAL study itself.

Why do high-impact sites matter for an oral agent?

For a field long dominated by injectable biologics, an oral therapy that holds IGA 0/1 in 70% of patients at two years — and clears genital disease in 89% — addresses a distinct practical problem. Scalp, genital, palmoplantar and nail psoriasis are notoriously refractory to topical therapy and difficult sites for many patients to self-treat.

The ICONIC-TOTAL design matters here as well. The investigators reported responder rates among patients who remained on therapy and were assessed at each landmark, so the Week 112 figures describe durability in a treated cohort rather than a randomized comparison against placebo or an active comparator at that timepoint. Clinicians weighing the data should read the 70% figure as sustained-efficacy evidence in continuing patients.

The week-by-week pattern also carries clinical information. Skin endpoints moved early — a 10-point IGA 0/1 gain between Week 16 and Week 24 — while nail endpoints took a full year to approach their ceiling. That divergence has direct counseling value: patients with significant nail involvement can be told that measurable improvement continues well past the point at which cutaneous responses have largely stabilized.

What comes next?

With two-year durability, site-specific clearance across scalp, genital, palmoplantar and nail disease, and a safety profile unchanged through Week 112, the ICONIC-TOTAL dataset positions icotrokinra as a longer-term oral option for plaque psoriasis — and fuller peer-reviewed publication of the complete trial results will define how regulators and payers weigh it against established biologic therapy.